Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Search results

Found 2893 matches for

The Oxford Vaccine Group is an independent multi-disciplinary clinical trials and epidemiology group based at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford. OVG works towards the goal of developing new and improved vaccines for the prevention of infection in adults and children.

FCDO Minister meets with vaccine researchers

Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.

First in-human vaccine trial for Nipah virus

The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.

OVG professor named in New Year's Honours list

Matthew Snape, Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group (OVG) before moving to Moderna in August 2022, has been appointed Member of the Most Excellent Order of the British Empire (MBE) for services to Public Health, particularly during COVID-19 while working at the OVG.

Oxford Vaccine Group receives £7.8 million in research funding to fight pandemic and epidemic threats

Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.

New campaign hopes to boost jab numbers

Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.

OVG Researcher awarded prestigious NIHR Professorship

Daniela Ferreira, Professor of Respiratory Infection and Vaccinology at the University of Oxford’s Department of Paediatrics and the Department of Clinical Sciences at the Liverpool School of Tropical Medicine has been awarded one of six prestigious Research Professorships by the National Institute of Health and Care Research (NIHR).

CEPI funding announced for development of vaccine prototype

The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.

Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines

A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.

Future of Chair in Global Health secured with £5 million gift

The University of Oxford’s commitment to tackling major global health challenges has been strengthened following the endowment of a chair in global health and clinical development. The new permanent post was made possible by a £5 million donation from Brazilian healthcare organisation SAIL for Health.

First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)

Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).

First in-human trials commence for CCHF vaccine

A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.

University of Oxford partners with CEPI to counter the threat of future pandemics

The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.

Director of Global Operations at OVG recognised in the King’s Birthday Honours 2023

Dr Parvinder Aley, Director of Global Operations at the Oxford Vaccine Group, has been recognised and celebrated in the 2023 King’s Birthday Honours list. Dr Aley has been appointed an Officer of the Order of the British Empire (OBE) for services to vaccination during the COVID-19 pandemic.

Professor Sir Andrew Pollard reveals unique insights into the world of science in a new podcast

Oxford Vaccine Group and Pandemic Sciences Institute’s Professor Pollard speaks to the people who shaped the COVID-19 pandemic in his new podcast, The Oxford Colloquy.

Britain’s Covid research led the world – why have our clinical trials fallen off a cliff?

Pressures on the NHS, a lack of doctors and post-Brexit delays are hampering our ability to develop cutting-edge drugs.

New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Load More